Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding study of tobramycin inhalation powder in non-cystic fibrosis bronchiectasis with pulmonary Pseudomonas aeruginosa infection
2015-003040-39Phase 2Terminated
- Sponsor
- Novartis
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tobramycin in Pseudomonal infection and bronchiectasis (4 arms), sponsored by Novartis. Started Aug 2016; status: terminated.
02
Drugs
tobramycin
03
Conditions
Pseudomonal infectionbronchiectasis
Beyond the preview
Go deeper on 2015-003040-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003040-39.